SCHEMBL3101476

SCHEMBL3101476

O=C(Nc1c(Cl)cncc1Cl)C(=O)c1cn(Cc2ccc(F)cc2)c2ccc(F)cc12

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 15/20 0.89
PDE4B Q07343 15/20 0.89
PDE4C Q08493 15/20 0.89
PDE4D Q08499 15/20 0.89
TUBB4A P04350 1/20 0.48
TUBB P07437 1/20 0.48
TUBA3C P0DPH7 1/20 0.48
TUBA1B P68363 1/20 0.48
TUBA4A P68366 1/20 0.48
TUBB4B P68371 1/20 0.48
TUBB3 Q13509 1/20 0.48
TUBB2A Q13885 1/20 0.48
TUBB8 Q3ZCM7 1/20 0.48
TUBA3E Q6PEY2 1/20 0.48
TUBA1A Q71U36 1/20 0.48
TUBA1C Q9BQE3 1/20 0.48
TUBB6 Q9BUF5 1/20 0.48
TUBB2B Q9BVA1 1/20 0.48
TUBB1 Q9H4B7 1/20 0.48
IDO1 P14902 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Awd-12-281 SCHEMBL155120 0.94 PDE4A (1.00) PDE4APDE4BPDE4CPDE4DTUBB4A
Awd-12-281 SCHEMBL29413256 0.94 PDE4A (1.00) PDE4APDE4BPDE4CPDE4DTUBB4A
Awd-12-281 SCHEMBL5638122 0.93 PDE4A (0.98) PDE4APDE4BPDE4CPDE4DTUBB4A
Awd-12-281 SCHEMBL5638136 0.93 PDE4A (0.98) PDE4APDE4BPDE4CPDE4DTUBB4A
SCHEMBL5636873 0.90 PDE4A (0.78) PDE4APDE4BPDE4CPDE4DTHRB
SCHEMBL5639794 0.88 PDE4A (0.76) PDE4APDE4BPDE4CPDE4DTUBB4A
SCHEMBL5637675 0.88 PDE4A (0.85) PDE4APDE4BPDE4CPDE4DTUBB4A
SCHEMBL6255980 0.88 PDE4A (0.89) PDE4APDE4BPDE4CPDE4DTUBB4A
SCHEMBL5893957 0.86 PDE4A (0.75) PDE4APDE4BPDE4CPDE4DTUBB4A
SCHEMBL5637676 0.84 PDE4A (0.82) PDE4APDE4BPDE4CPDE4DTUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180318271-A1 Use of PDE4 Inhibitors for the Prophylaxis and/or Therapy of Dyslipoproteinaemia and Related Disorders ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) 2018-11-08 US claimed
WO-2017080919-A1 USE OF PDE4 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF DYSLIPOPROTEINAEMIA AND RELATED DISORDERS ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) 2017-05-18 WO claimed
EP-3165224-A1 USE OF PDE4 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF DYSLIPOPROTEINAEMIA AND RELATED DISORDERS Albert-Ludwigs-Universität Freiburg (DE) 2017-05-10 EP claimed
US-20150119399-A1 BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2015-04-30 US claimed
EP-2804603-A1 BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE President and Fellows of Harvard College (US) 2014-11-26 EP claimed
WO-2013106547-A1 BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-07-18 WO claimed
EP-1849468-A2 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist Nycomed GmbH (DE) 2007-10-31 EP claimed
US-20060148804-A1 Pde4 inhibitors for the treatment of neoplasms of lymphoid cells NYCOMED GMBH (DE) 2006-07-06 US claimed
US-20060079540-A1 Pde4 and pde3/4 inhibitors for use in the treatment of cachexia ALTANA PHARMA AG (DE) 2006-04-13 US claimed
EP-1587512-A2 PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS ALTANA Pharma AG (DE) 2005-10-26 EP claimed
EP-1448202-A1 COMBINATION OF A PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG ALTANA Pharma AG (DE) 2004-08-25 EP claimed
WO-2004062671-A2 PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS ALTANA PHARMA AG (DE) 2004-07-29 WO claimed
EP-1429843-A2 COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST ALTANA Pharma AG (DE) 2004-06-23 EP claimed
EP-1429807-A2 COMBINATION OF A NSAID AND A PDE-4 INHIBITOR ALTANA Pharma AG (DE) 2004-06-23 EP claimed
WO-2004047817-A1 PDE4 AND PDE3/4 INHIBITORS FOR USE IN THE TREATMENT OF CACHEXIA ALTANA PHARMA AG (DE) 2004-06-10 WO claimed
WO-2003074055-A1 PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST ALTANA PHARMA AG (DE) 2003-09-12 WO claimed
WO-2003039552-A1 COMBINATION OF PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG ALTANA PHARMA AG (DE) 2003-05-15 WO claimed
US-20030092706-A1 Combination NYCOMED GMBH (DE) 2003-05-15 US claimed
WO-2003024489-A2 COMBINATION OF A NSAID AND A PDE-4 INHIBITOR ALTANA PHARMA AG (DE) 2003-03-27 WO claimed
WO-2003024488-A2 COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST ALTANA PHARMA AG (DE) 2003-03-27 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079540-A1 Pde4 and pde3/4 inhibitors for use in the treatment of cachexia PDE4A, PDE12, PDE4B PDE4A 1/4885PDE4B 3/4885PDE4C 7/4885
US-20060148804-A1 Pde4 inhibitors for the treatment of neoplasms of lymphoid cells PDE4A, PDE4B, PDE4C PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885
US-20150119399-A1 BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE IAPP, GPR119, PCNA PDE4A 1173/4885PDE4B 1204/4885PDE4C 1042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.